Inhibitor risk and factor VIII brands in three hemophilia cohort studies
| Author . | Study . | No. HTCs . | No. PUPs . | Follow-up (E.D.) . | Timespan . | Inhibitor rate (%) . | Adjusted HR for second- vs third-generation FVIII* . |
|---|---|---|---|---|---|---|---|
| Calvez et al1 | FranceCoag PUP cohort | 12 | 303 | 75 | 2000-2009 | 37.6 | 1.55 (0.97-2.49) |
| Collins et al2 | UK National Haemophilia Database | 9 | 407 | 50 | 2000-2011 | 29.5 | 2.17 (0.99-4.74) |
| Gouw et al7 | Research of Determinants of Inhibitor Development (RODIN) study | 29 | 547 | 75 | 2000-2010 | 32.4 | 1.60 (1.08-2.37) |
| Author . | Study . | No. HTCs . | No. PUPs . | Follow-up (E.D.) . | Timespan . | Inhibitor rate (%) . | Adjusted HR for second- vs third-generation FVIII* . |
|---|---|---|---|---|---|---|---|
| Calvez et al1 | FranceCoag PUP cohort | 12 | 303 | 75 | 2000-2009 | 37.6 | 1.55 (0.97-2.49) |
| Collins et al2 | UK National Haemophilia Database | 9 | 407 | 50 | 2000-2011 | 29.5 | 2.17 (0.99-4.74) |
| Gouw et al7 | Research of Determinants of Inhibitor Development (RODIN) study | 29 | 547 | 75 | 2000-2010 | 32.4 | 1.60 (1.08-2.37) |
E.D., exposure days; FVIII, factor VIII; HTC, hemophilia treatment center.
Adjusted HRs did not change after excluding those participating in the RODIN study: 50 of 303 (16.5%) in the French cohort and 88 of407 (21.6%) of the UK cohort.